Aeshah A AlAzmi
Overview
Explore the profile of Aeshah A AlAzmi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alkharouby R, Aljehani N, Alsubaie N, Alqarni A, Hariri M, Elimam N, et al.
Cureus
. 2023 Oct;
15(9):e46149.
PMID: 37900520
Introduction Clinical data about the first and second most prominent waves of SARS-CoV-2 among pediatric cancer patients were inconsistent. This study aims to retrospectively report the clinical characteristics and outcomes...
2.
Al Blewi S, AlAzmi A, Elimam N, Jastaniah W, Mohammedkhalil A, Abdullah S
Cureus
. 2023 Feb;
15(1):e33533.
PMID: 36779104
Introduction Tumor lysis syndrome (TLS) is a life-threatening metabolic abnormality. The incidence of TLS depends on the underlying malignancy. In a recent analysis of hematological malignancy, the incidence of clinical...
3.
AlAzmi A, Alnajjar F, AlShomrani M
J Oncol Pharm Pract
. 2020 Nov;
26(8):1942-1946.
PMID: 33131451
Introduction: The COVID-19 pandemic has led to significant changes in all governmental activities in Saudi Arabia including training and teaching, with the majority of such activities suspended in response to...
4.
AlAzmi A, Jastaniah W, Alhamdan H, AlYamani A, AlKhudhyr W, Abdullah S, et al.
JCO Glob Oncol
. 2020 Mar;
6:476-485.
PMID: 32202921
Purpose: Cancer treatment shortages are complex and a persistent problem worldwide. Patients with cancer are most vulnerable to drug shortages, which provides opportunities to examine the extent of the challenge(s)...
5.
Algethami A, Alshamrani M, AlHarbi A, AlAzmi A, Khan M, AlHadidi R
J Oncol Pharm Pract
. 2020 Mar;
27(1):20-25.
PMID: 32151186
Backgroud: Oral medications are commonly prescribed for many cancer patients. Unfortunately, most of them are dispensed without proper counseling about handling practices. We aimed to evaluate the handling, storage, and...
6.
AlAzmi A, Alhamdan H, Ahmed O, Tomlin S, Rashed A
Int J Pharm Pract
. 2019 Jun;
27(6):578-581.
PMID: 31168945
Objectives: To determine the impact of a computerised physician order entry (CPOE) system on the drug-related problems' (DRPs) incidence and characteristics in hospitalised children in a Saudi hospital, and to...
7.
Jastaniah W, Elimam N, Abdalla K, AlAzmi A, Algamal A, Felimban S
Hematology
. 2019 Mar;
24(1):369-377.
PMID: 30885098
Objectives: Acute lymphoblastic leukemia (ALL) with CNS2 status predicts inferior outcome and a high rate of CNS relapse, similar to overt CNS leukemia (CNS3). The purpose of this study was...
8.
Mustafa O, Abdalla K, AlAzmi A, Elimam N, Abrar M, Jastaniah W
J Oncol Pharm Pract
. 2018 Dec;
25(8):1831-1838.
PMID: 30518307
Background: Outcomes of relapsed/refractory childhood acute leukemia remain poor. We analyzed the safety/efficacy of fludarabine, cytarabine, and granulocyte colony stimulating factor, with/without idarubicin (FLAG ± IDA) as salvage therapy compared...
9.
Jastaniah W, Elimam N, Abdalla K, AlAzmi A, Elgaml A, Alkassar A, et al.
Exp Hematol Oncol
. 2018 Nov;
7:29.
PMID: 30479872
Background: Refinement of risk-based treatment stratification by minimal residual disease (MRD) at different time points has improved outcomes of childhood acute lymphoblastic leukemia (ALL). In this prospective study we evaluated...
10.
Jastaniah W, Elimam N, Abdalla K, AlAzmi A, Aseeri M, Felimban S
Leuk Res Rep
. 2018 Nov;
10:44-51.
PMID: 30416957
Sixty-three children (1-14 years of age) newly diagnosed with T-cell acute lymphoblastic leukemia were treated from January 2001 to December 2014. Patient outcomes were evaluated based on the regimen received;...